Competing Risks Analysis of the Finnish Diabetes Prevention Study.

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Moustafa M A Ibrahim, Matti Uusitupa, Jaakko Tuomilehto, Jaana Lindström, Maria C Kjellsson, Mats O Karlsson
{"title":"Competing Risks Analysis of the Finnish Diabetes Prevention Study.","authors":"Moustafa M A Ibrahim, Matti Uusitupa, Jaakko Tuomilehto, Jaana Lindström, Maria C Kjellsson, Mats O Karlsson","doi":"10.1002/psp4.70065","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical studies often observe one interesting event in the presence of other competing events. When both types of events can occur at any time but are only observed at clinical visits (i.e., interval censored), standard survival models may introduce bias in the estimated incidence of the interesting event over time. This can also lead to inflated relative differences between treatment groups. We developed a multi-state model for competing risks analysis of interval censored data from the Finnish Diabetes Prevention Study. The developed model predicted the participants' clinical outcomes and demonstrated that lifestyle changes significantly decreased the risk of both diabetes and death. The model showed that those who dropped out were at lower risk of developing diabetes, neglecting the assumption of independent censoring. Furthermore, the model identified the most important covariates predicting the future development of diabetes, which should be targeted for therapeutic intervention in likely clinical scenarios. These covariates are baseline BMI, HbA1c, and insulin sensitivity measurements by QUICKI for the onset of developing T2DM, baseline BMI for dropping out, and sex and age as the predictive covariates of death. Trial Registration: ClinicalTrials.gov identifier: NCT00518167.</p>","PeriodicalId":10774,"journal":{"name":"CPT: Pharmacometrics & Systems Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CPT: Pharmacometrics & Systems Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/psp4.70065","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Clinical studies often observe one interesting event in the presence of other competing events. When both types of events can occur at any time but are only observed at clinical visits (i.e., interval censored), standard survival models may introduce bias in the estimated incidence of the interesting event over time. This can also lead to inflated relative differences between treatment groups. We developed a multi-state model for competing risks analysis of interval censored data from the Finnish Diabetes Prevention Study. The developed model predicted the participants' clinical outcomes and demonstrated that lifestyle changes significantly decreased the risk of both diabetes and death. The model showed that those who dropped out were at lower risk of developing diabetes, neglecting the assumption of independent censoring. Furthermore, the model identified the most important covariates predicting the future development of diabetes, which should be targeted for therapeutic intervention in likely clinical scenarios. These covariates are baseline BMI, HbA1c, and insulin sensitivity measurements by QUICKI for the onset of developing T2DM, baseline BMI for dropping out, and sex and age as the predictive covariates of death. Trial Registration: ClinicalTrials.gov identifier: NCT00518167.

芬兰糖尿病预防研究的竞争风险分析
临床研究经常观察到一个有趣的事件在其他竞争事件的存在。当这两种类型的事件在任何时间都可能发生,但仅在临床就诊时观察到(即,间隔剔除),标准生存模型可能会在随时间估计的感兴趣事件发生率中引入偏差。这也可能导致治疗组之间的相对差异膨胀。我们开发了一个多状态模型,用于芬兰糖尿病预防研究的间隔审查数据的竞争风险分析。开发的模型预测了参与者的临床结果,并证明生活方式的改变显著降低了患糖尿病和死亡的风险。该模型显示,那些辍学的人患糖尿病的风险较低,忽略了独立审查的假设。此外,该模型确定了预测糖尿病未来发展的最重要协变量,这些协变量应该在可能的临床情况下针对治疗干预。这些协变量包括基线BMI、糖化血红蛋白(HbA1c)和由QUICKI测量的用于发展为T2DM的胰岛素敏感性,基线BMI用于退出,以及性别和年龄作为死亡的预测协变量。试验注册:ClinicalTrials.gov标识符:NCT00518167。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.00
自引率
11.40%
发文量
146
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信